Asthma News: Monoclonal Antibody Reduces Asthma Attacks in Urban Youth

Mepolizumab decreased asthma attacks by 27% in Black and Hispanic children and adolescents.

Thursday, August 11, 2022 Monoclonal Antibody Reduces Asthma Attacks in Urban Youth Illustration of a child using an asthma inhaler in an urban setting. Cells called eosinophils, present at high levels in the blood and airways of many people with untreated asthma, appear in the lower third of the illustration. Credit: NIAID A monoclonal antibody, mepolizumab, decreased asthma attacks by 27% in Black and Hispanic children and adolescents who have a form of severe asthma, are prone to asthma attacks and live in low-income urban neighborhoods, a NIAID clinical trial has found. This population has been underrepresented in previous clinical trials of asthma therapeutics. The findings were published today in the journal The Lancet. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107